Multi-Source Validation Supply-side: manufacturers, distributors, channel partners Demand-side: buyers, end-users, customer panels Macro data: industry benchmarks, economic indicators Analytical Methods Bottom-up & top-down market sizing Regression analysis and forecasting Sensitivity and scenario modeling Forecasting Models Time-series analysis on historical data patterns S-curve adoption modeling for emerging technologies Scenario modeling - best, base, and worst case Key Deliverables Total market size (USD & units) CAGR by segment Geographic & industry forecasts Growth drivers and inhibitors Sample Market Forecast $450B2023 $520B2024 $610B2025 $720B2026 $850B2027 CAGR 17.2% 2023 2027 Core Analysis Market share by competitor Product feature benchmarking Pricing strategy mapping SWOT & positioning matrices Advanced Analysis Win-loss analysis GTM strategy decoding Organizational capabilities benchmark White space opportunity matrix Strategic Outputs Validated Insights - beyond raw data, actionable intelligence White Space Mapping - underserved opportunities Market Entry Strategy - optimal go-to-market approach Execution Levers Pricing Strategy - value-based positioning Channel Strategy - distribution optimization Risk Mitigation - scenario planning & hedging Visualization Toolkit Market Sizing Dashboards Historical & forecast trends across geographies and segments

GLP-1 - A Physiological Process Researchers are still trying to nail down exactly how GLP-1 antagonist receptors work to reduce alcohol cravings and consumption, but the theory is that it works for the same reason that it leads to weight loss
5 mm is sufficient
As of July 2026, following a March 2026 strategic shift, Hims no longer advertises compounded GLP-1s and sells only FDA-approved branded medication (Wegovy, Zepbound, and the newer oral GLP-1 Foundayo)
doi:10.1016/j.japh.2020.06.023 48
The First 30 Days: The Adaptation Phase Treatment typically begins with a low induction dose for the first four weeks